Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Enhertu Delivers Stellar PIII Data in HER2 Low Breast Cancer
Daiichi Sankyo said on June 5 that its antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) reduced the risk of disease progression or death by 50% versus chemotherapy in a global PIII trial enrolling patients with HER2 low breast cancer. The DESTINY-Breast04…
To read the full story
Related Article
- Enhertu Wins EU Approval for HER2 Low Breast Cancer
January 27, 2023
- Enhertu Nabs EU Nod for Second-Line Gastric Cancer, CHMP OK for HER2 Low Breast Cancer
December 20, 2022
- Enhertu Grabs US Approval for HER2 Low Breast Cancer: Daiichi Sankyo/AZ
August 9, 2022
- Enhertu Gets FDA’s Priority Review for HER2 Low Breast Cancer
July 26, 2022
- Enhertu Filed for HER2 Low Breast Cancer in Japan: Daiichi Sankyo
June 28, 2022
- EMA Starts Enhertu Review for HER2 Low Breast Cancer
June 23, 2022
- Enhertu Hits PFS, OS Goals in HER2 Low Breast Cancer
February 22, 2022
BUSINESS
- PMP Returns Slam Drug Makers' Leading Products, Prazaxa Cut 45%: Jiho Poll
March 13, 2026
- Lilly to Invest Additional 20 Billion Yen in Japan's Seishin Plant
March 13, 2026
- Fujifilm Invests in Austria’s Valanx Biotech to Boost ADC Technology
March 13, 2026
- Merck, CDMO Cyto-Facto Join Hands on Cell and Gene Therapy
March 13, 2026
- Anti-PD-1 Agonist Antibody Enters PI in Australia for Autoimmune Diseases: Meiji
March 13, 2026
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…